Tachmed and Paragraf Announce Strategic Partnership to Scale Graphene-Powered Diagnostics
Somersham, UK – Tachmed, an innovative medtech company, and Paragraf, the world’s first mass producer of graphene-based electronic devices using standard semiconductor processes, have entered into a strategic partnership to bring scalable, cost-effective, and accurate diagnostic testing to homes and primary care clinics globally.
The partnership will focus on the integration of Paragraf’s proprietary graphene field-effect transistor (GFET) molecular sensor into Tachmed’s innovative digital health platform, TachShield. This cloud-based system combines rapid diagnostic tests, connected devices, software, and APIs through a single mobile app, offering a seamless experience for patients, health service providers, and clinicians.
Under the terms of the agreement, the companies are entering an agreement to co-develop next-generation diagnostic tests based on GFET biosensors; and ensure Tachmed can scale up supply of the -home test cartridges.
“This partnership marks a major milestone in Tachmed’s journey to transform access to precise, real-time health diagnostics,” said Paul Christie, Founder and CEO of Tachmed. “We’ve already demonstrated the potential of TachShield, and now, in working closely with Paragraf, we have the opportunity to scale that impact exponentially. We aren’t just advancing diagnostics, we’re helping to build a future where early detection can become a reality for everyone, everywhere.”
TachShield, powered by Paragraf’s GFET sensors, will help drive health equality by enabling rapid testing in homes, community health centres, frontline clinics, and remote locations. The integrated solution will support chronic and infectious disease detection at scale and provides users with real-time, actionable health insights.
Paragraf’s new advanced Graphene foundry in Huntingdon, Cambridgeshire will play a key role in supporting the anticipated high-volume demand from Tachmed’s global partners.
“This collaboration with Tachmed allows us to apply our cutting-edge GFET technology where it can make the most immediate human impact,” said Simon Thomas, Paragraf CEO. “By enabling precision diagnostics in everyday settings, we can truly reshape how people engage with their health.”
The partnership will prioritize strategic markets in the Middle East, the UK, the USA, and Asia, leveraging Tachmed’s ongoing work with health system providers and its partnerships with AWS and Anthropic. These AI and cloud capabilities are being used to enhance assay development and next-generation diagnostic intelligence.
TachMed has successfully raised $10 million in seed funding to support its rollout strategy in coordination with health providers and agencies focused on early disease detection and public health resilience. The company is now in its Series A funding round.’
ENDS
About Paragraf
Paragraf is the first company in the world to mass produce graphene-based electronic devices using standard semiconductor processes. Its line of graphene products includes GFET based sensing solutions which make use of the proprietary graphene growth and device assembly processes to fully harness graphene’s many advanced features.
https://www.paragraf.com
About Tachmed
Tachmed is a digital health data company offering a cost effective proprietary and groundbreaking cloud platform called TachShield. This combines rapid in vitro diagnostic tests, devices and software/APIs through one mobile app for use at home and in frontline primary health clinics. Patients will access the system through their health service provider enabling integrated fast and convenient online services such as telehealth and pharmacy.
https://tachmed.com
